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Abstract
Defining the pharmacological target(s) of currently used drugs and developing new analogues with greater potency are
both important aspects of the search for agents that are effective against drug-sensitive and drug-resistant Mycobacterium
tuberculosis. Thiacetazone (TAC) is an anti-tubercular drug that was formerly used in conjunction with isoniazid, but
removed from the antitubercular chemotherapeutic arsenal due to toxic side effects. However, several recent studies have
linked the mechanisms of action of TAC to mycolic acid metabolism and TAC-derived analogues have shown increased
potency against M. tuberculosis. To obtain new insights into the molecular mechanisms of TAC resistance, we isolated and
analyzed 10 mutants of M. tuberculosis that were highly resistant to TAC. One strain was found to be mutated in the
methyltransferase MmaA4 at Gly101, consistent with its lack of oxygenated mycolic acids. All remaining strains harbored
missense mutations in either HadA (at Cys61) or HadC (at Val85, Lys157 or Thr123), which are components of the b-
hydroxyacyl-ACP dehydratase complex that participates in the mycolic acid elongation step. Separately, a library of 31 new
TAC analogues was synthesized and evaluated against M. tuberculosis. Two of these compounds, 15 and 16, exhibited
minimal inhibitory concentrations 10-fold lower than the parental molecule, and inhibited mycolic acid biosynthesis in a
dose-dependent manner. Moreover, overexpression of HadAB HadBC or HadABC in M. tuberculosis led to high level
resistance to these compounds, demonstrating that their mode of action is similar to that of TAC. In summary, this study
uncovered new mutations associated with TAC resistance and also demonstrated that simple structural optimization of the
TAC scaffold was possible and may lead to a new generation of TAC-derived drug candidates for the potential treatment of
tuberculosis as mycolic acid inhibitors.
Citation: Coxon GD, Craig D, Corrales RM, Vialla E, Gannoun-Zaki L, et al. (2013) Synthesis, Antitubercular Activity and Mechanism of Resistance of Highly Effective
Thiacetazone Analogues. PLoS ONE 8(1): e53162. doi:10.1371/journal.pone.0053162
Editor: Jean Louis Herrmann, Hopital Raymond Poincare - Universite Versailles St. Quentin, France
Received September 22, 2012; Accepted November 26, 2012; Published January 3, 2013
Copyright:  2013 Coxon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the InfectioPoˆle Sud (to RMC). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: laurent.kremer@univ-montp2.fr (LK); geoff.coxon@strath.ac.uk (GDC)
Introduction
Drug-resistant Mycobacterium tuberculosis is an increasing threat to
global health [1,2]. New drugs to treat tuberculosis are urgently
needed, yet the pace of new drug development has been slow. Few
new drug targets have been validated despite considerable
advances in our understanding of M. tuberculosis biochemistry,
metabolism and identification of many essential genes and
pathways [3]. While it has become apparent that not all essential
metabolic processes represent good drug targets [4], years of drug
development efforts have shown that the bacterial cell wall is an
excellent target for antibacterials [5,6,7]. Several successful
antitubercular drugs, including isoniazid (INH) and ethionamide
(ETH), inhibit enzymes required for mycolic acid synthesis [5,8,9].
Mycolic acids are C60-C90 branched-chain b-hydroxylated fatty
acids that are covalently bound to arabinogalactan-peptidoglycan
forming the skeleton of the cell wall [10]. They are also found in
the abundant non-covalently associated outer membrane ester
glycolipids trehalose monomycolates (TMM) and trehalose
dimycolates (TDM) [11] or as free lipids in mycobacterial biofilms
[12]. Two major mycolic acid classes based on chemical
modifications in the meromycolate can be distinguished: the a-
mycolic acids possess two cyclopropane rings, while the oxygen-
ated mycolic acids, such as keto- and methoxy-mycolates possess
oxygen functions [10]. Mycolic acids display important charac-
teristics such as permeability to antibiotics and persistence within
the infected host [13,14,15].
The biosynthetic machinery of mycolates involves type I and
type II fatty acid synthases, FAS-I and FAS-II, respectively [10].
FAS-II is composed of four dissociable enzymes that act
successively and reiteratively to elongate the growing acylated-
acyl carrier protein (ACP). FabH links FAS-I and FAS-II,
providing a b-ketoacyl-ACP product with two added carbon
atoms which is then reduced by the reductase MabA, followed by
a dehydratation step carried out by the set of dehydratases
HadABC and then reduction by the enoyl-ACP reductase InhA.
The subsequent steps of elongation of the growing acyl-ACP chain
with the condensation of a malonyl-ACP unit at each round are
performed by the condensases KasA and KasB [16]. Most FAS-II
enzymes are unique and essential, thus representing excellent drug
targets.
There is a vital need for the discovery and development of new
antitubercular drugs that can shorten the treatment of drug-
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sensitive M. tuberculosis and are also active against strains of the
organism resistant to the currently used drugs. One way to find
new agents is to identify the pharmacological targets of currently
used drugs and then develop new therapeutic analogues with
greater potency, better pharmacokinetics (PK) and less toxicity.
When multi-drug or extensive-drug resistance leads to treatment
failure with first-line and even second-line anti-TB drugs, all
alternative agents are considered, including thiocarbamide drugs
such as ethionamide (ETH) thiacetazone (TAC) or isoxyl (ISO),
even though these have often shown unacceptable levels of toxic
side-effects. However, once their cellular target(s) and mode of
action have been discovered and characterized, one could envisage
the development of new, more potent drugs attacking the same
target(s), but with reduced side-effects.
Many current antitubercular drugs require some form of
cellular activation to unmask reactive groups that will bind to
their specific targets. ETH, TAC and ISO are all pro-drugs that
must be enzymatically activated by the monooxygenase EthA [17].
Expression of EthA is transcriptionally repressed by EthR [18,19],
so when EthR is overexpressed, it blocks ethA transcription,
thereby generating ETH resistance. Conversely, in the absence of
EthR, EthA is overproduced, leading to hypersusceptibility to the
drug. Thus, the drug resistance phenotype in clinical isolates can
be caused by the lack of drug activation in the target
mycobacteria.
Our previous work demonstrated that in M. bovis BCG, M.
chelonae and M. marinum, TAC inhibits the methyltransferases that
introduce cyclopropane rings into mycolates [20]. Members of this
methyltransferase family of enzymes include PcaA, CmaA2 and
MmaA2, which are all important in the pathophysiology of
mycobacteria [13,21,22]. However, inhibition of these enzymes is
unlikely to explain the antitubercular activity of TAC. TAC-
resistant BCG mutants lacking keto-mycolates were identified and
found to possess mutations within the mmaA4, which encodes a
methyltransferase required for the synthesis of methoxy- and keto-
mycolic acids [23]. In addition, we also found several highly
resistant TAC mutants without mutations in either ethA or mmaA4,
suggesting that resistance could be mediated by mutations in
additional gene(s) [23]. Recently, it was observed that TAC
inhibits mycolic acid biosynthesis in M. tuberculosis and M. kansasii
and that resistance was associated with mutations in the hadABC
operon [24]. That this suggests that the FAS-II dehydratase
complex represents a new player in the resistance to this
antitubercular compound is also supported by the recent findings
that treating M. tuberculosis with TAC results in the accumulation of
3-hydroxy fatty acids, the substrates of the dehydratase [25].
The present study, a continuation to our efforts to decipher the
mechanisms of resistance and action of TAC, confirmed these
recent results and prompted us to synthesize and evaluate the
antitubercular activity of a simple series of new TAC analogues.
Materials and Methods
Mycobacterial Strains and Growth Conditions
M. bovis BCG strain Pasteur 1173P2 and M. tuberculosis mc27000
[26] were all grown either on Middlebrook 7H10 agar enrichment
or in Sauton’s broth medium supplemented with oleic acid-
dextrose-catalase (OADC) at 37uC. For M. tuberculosis mc27000,
media were supplemented with 24 mg/ml pantothenic acid.
Spontaneous mc27000 mutants, resistant to high levels of either
TAC or SRI-224 were selected by diluting and plating mid-log
phase cultures at approximately 16 108 cells/ml on 7H10 agar
medium containing either 2.5, 5 or 10 mg/ml of TAC or SRI-224.
Plates were incubated at 37uC up to 4 weeks. Single colonies were
picked, grown in Sauton’s medium and maintained in culture
without drug.
DNA Manipulation, Sequencing and Genetic Constructs
Sequence of mmaA4, ethA, hadA, hadB and hadC genes in the
various M. tuberculosis resistant mutants was obtained from PCR
amplicons of the concerned genomic region using the primers
listed in Table 1. PCR was done using the high fidelity polymerase
from Euromedex, and the resulting products were purified using
the PCR clean-up system (Qiagen) and directly sequenced.
To generate the pMV261_hadABC construct, the hadABC gene
cluster was PCR amplified using primers HadAF-261 and hadCR-
261 using M. tuberculosis genomic DNA. The amplicon was then
restricted by MscI/EcoRI and ligated into the E. coli-mycobacte-
rial shuttle vector pMV261 containing the hsp60 promoter [27] cut
with the same enzymes. Integrity of the construct was verified by
nucleotide sequencing. The pMK1_hadAB and pVV16_hadBC
constructs allowing to produce in mycobacteria the N-terminal
and C-terminal His-tagged heterodimers HadAB and HadBC,
respectively, were reported previously [28]. Constructs allowing
overexpression HadAB, HadBC or HadABC we used to transform
M. tuberculosis mc27000, and transformants were selected on 7H10
agar containing OADC, 25 mg/ml kanamycin and 24 mg/ml
pantothenate. Plates were incubated at 37uC for 2–3 weeks.
RNA Extraction and Quantitative Real Time-PCR
5 ml cultures at A600 of 0.8-1 were harvested, immediately
resuspended in 1 ml of RNA protect reagent (Qiagen), incubated
for 1 hr at room temperature and finally resuspended in 1 ml of
RLT buffer from the RNeasy kit (Qiagen). Subsequently, bacteria
were transferred to a Lysing matrix B tube (MP Bio), processed in
a bead beater apparatus for 45 s at maximal speed three times,
and held on ice before centrifugation. Supernatants (750 ml) were
mixed with 525 ml of ethanol, and RNA was purified with the
RNeasy kit according to the manufacturer’s instructions (Qiagen).
Contaminating DNA was removed following DNase I treatment
(Invitrogen). RNA integrity was analyzed on a BioAnalyzer 2100
machine from Agilent, using RNA nano series II chips. Double-
stranded cDNA was produced using the Superscript III reverse
transcriptase (Invitrogen) as described by the manufacturer.
Quantitative PCR were performed using an in-house SYBR
Green mixture and Lightcycler 480 II (Roche Applied Science), as
described previously [29]. The PCR program consisted of initial
denaturation at 98uC for 3 min, 45 cycles of 98uC for 5 s, 68uC for
10 s and 72uC for 10 s. HadAB and HadBC genes were amplified
with specific primers (Table 1). Crossing point values, given as
cycle numbers, were normalized to values obtained for the
mycobacterial household gene sigA. Primer efficiencies, deter-
mined as described previously [29], were between 1.9 and 2.
Mycolic Acid Analysis
Extraction of cell wall mycolic acids from mycobacterial cells
was carried out as previously described [17]. Briefly, cell pellets
were washed and treated with 15% tetrabutyl ammonium
hydroxide (TBAH) at 100uC overnight. Mycolic acids were
methyl-esterified and extracted in diethyl ether. Extracts were
dried and resuspended in dichloromethane for application to a
silica-coated plate for thin layer chromatography (TLC). Myco-
lates were resolved on normal phase TLC in hexane/ethyl acetate
(19/1, v/v). Lipids were visualized by spraying the TLC plate with
5% molybdophosphoric acid (MPA) in ethanol followed by
charring with a heat gun.
For visualizing drug-induced changes in the mycolates profile,
increasing drug concentrations of TAC or related analogues were
Efficient TAC Analogues against M. tuberculosis
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added to the growth medium for 14 hours. Metabolic labeling of
lipids was performed by adding 1 mCi/ml of [2-14C]acetate
(56 mCi/mmol, Amersham Biosciences) for an additional 6 hours
at 37uC, followed by harvesting of the cells and extraction of
mycolates as described above. Autoradiograms were obtained by
overnight exposure to Kodak Biomax MR film to reveal [14C]-
labeled lipids. In case of silica plates impregnated with 10% silver
nitrate, hexane/ethyl acetate (19:1, v/v) was used for three runs.
Two-dimensional TLC on silver nitrate-impregnated plates was
carried out with hexane/ethyl acetate (19/1, v/v), twice in the first
dimension, followed by petroleum ether/diethyl ether (17/3, v/v)
three times in the second dimension.
Drug Susceptibility Testing
Susceptibility of M. tuberculosis mc27000 and clinical isolates to
the various TAC analogues was determined on Middlebrook
7H10 solid medium containing OADC enrichment with increas-
ing drug concentrations as reported earlier [17]. Serial 10-fold
dilutions of each actively growing culture were plated and
incubated at 37uC for two weeks. The minimal inhibitory
concentration (MIC) was defined as the minimum concentration
required to inhibit 99% of the growth.
Reagents and Apparatus
Melting point determination was performed using a Stuart
Scientific Melting Point SMP1 apparatus with degrees Celsius as
the unit. Infra-red spectra were run on Jasco FT-IR-4200 ATR
(Attenuated Total Reflection Mode) and Mattson Genesis Series
FT-IR spectrometers with samples compressed with KBr into
disks. Wavenumbers, (nmax) are expressed as cm
–1. Proton nuclear
magnetic resonance (1H NMR) and carbon (13C NMR) spectra
were run on a JEOL Lambda delta 400 (400 MHz) spectrometer.
Chemical shifts are stated in parts per million (ppm) and
multiplicity indicated as singlet (s), doublet (d), triplet (t), quartet
(q), and multiplet (m). Coupling constants (J) are quoted in Hertz
(Hz) and deuterated solvents specified for each of the compounds.
Elemental analysis was performed on Perkin Elmer 2400
Analyzer. Standard methods were used to determine C, H, and
N simultaneously and halogens separately. Unless otherwise
stated, all reagents and solvents were obtained from commercial
sources. Solvents were dried according to standard procedures
when deemed necessary.
Chemical Synthesis of TAC Analogues
Synthesis of benzylidienehydrazinecarbothiamide (1) as a
general procedure for the preparation of TAC
analogues. Thiosemicarbazide, or derivative thereof, (0.91 g,
10 mmol, 1.0 eq) and glacial acetic acid (0.5 ml) were added to a
stirring solution of benzaldehyde (1.1 g, 10 mmol, 1.0 eq)
dissolved in absolute ethanol (10 ml). The mixture was refluxed
for 3 hours before cooling and standing for 18 hours to afford a
crude white powder. The solid was recrystalised using ethanol
(95%), filtered and washed with cold ethanol to give 1 as a pure
white solid (1.20 g 67.4%). m.p 163–164uC; 1H NMR (400 MHz,
DMSO-d6) d 9.70 (1H, s), 7.86 (1H, s), 7.63 (2H, d, J = 8.3 Hz),
7.41 (3H, d, J = 8.3 Hz), 6.44 (1H, s); 13C NMR (400 MHz,
DMSO-d6) d 182.9 (C=S), 145.1 (CH=N), 131.5 (Ar), 128.9 (Ar),
127 (Ar), 117.4 (Ar); umax (cm
–1): 3417.2, 3399.9, 3229.2 (NH),
1598 C=N bend, 1282 C=S stretch; CHN analysis Found: C,
53.65; H, 4.59; N, 23.36; S, 17.62. Required for C8H9N3O1S: C,
53.63; H, 5.03; N, 23.46; S, 17.88.
Synthesis of 4-methylbenzylidenehydrazinecarbothioamide
(2). The title compound was obtained as a white solid (1.6 g,
79.2%) using the general procedure.m.p 175–177uC; 1H NMR
(400 MHz, DMSO-d6) d 9.67 (2H, s), 7.85 (1H, s), 7.54 (2H, d,
J = 8.4 Hz), 7.21 (2H, d, J = 8.4 Hz), 6.37 (1H, s), 2.38 (3H, s); 13C
NMR (400 MHz, DMSO-d6) d 178.3 (C=S), 142.9 (C=N); 132.0
(Ar); 129.8 (Ar); 127.8 (Ar), 21.60 (CH); umax (cm
–1): 3380, 3236
(NH), 1595 (C=N), 1177 (C=S); CHN analysis Found: C, 55.96;
H, 5.43; N, 21.47; S, 16.12 Required for C9H11N3S: C, 55.96; H,
5.70; N, 21.76; S, 16.58.
Synthesis of 4-methylbenzylidene-N-methyl-hydrazine-
carbothioamide (3). The title compound was obtained as a
white solid (1.1 g, 71.5%) using the general procedure. m.p 181–
182uC; 1H NMR (400 MHz, DMSO-d6) d 10.45 (1H,s), 8.42
(1H,s), 7.78 (2H, d, J = 8.2 Hz), 7.41 (2H, d, J = 8.2 Hz), 2.92 (3H,
s), 2.31 (3H, s), 2.03 (2H, m); 13C NMR (400 MHz, DMSO-d6) d
178.4 (C=S), 147.0 (C=N), 140.9 (Ar), 132.6 (AR), 128.6 (Ar),
Table 1. Oligonucleotides used in this study.
Primer Sequence (59-39) Purpose
HadA-qRT-F gggcttgctggctccgttga qRT-PCR analysis of hadA
HadA-qRT-R gcccgccacgatcggtttct qRT-PCR analysis of hadA
HadC-qRT-F ccgcgggatgatttggcggt qRT-PCR analysis of hadC
HadC-qRT-R cggccgcttcctcgctcaaa qRT-PCR analysis of hadC
SigA-RT-F gcccgaggagctggccaaag qRT-PCR analysis of sigA
SigA-RT-R ccaagctggctgtcgccctc qRT-PCR analysis of sigA
HadA-F-261 caatggccatggcg ttgagcgcagacatcgttggga (MscI site underlined) Amplification of hadABC for cloning into pMV261
HadC-R-261 ccggaattcttacgcggtcctgatgacctgcccg (EcoRI site underlined) Amplification of hadABC for cloning into pMV261
HadA-F agttctgcccgaattgcggcaaacaccagg Amplification of hadABC for sequencing
HadC-R cctcggggttttcccaacatcggcgcgct Amplification of hadABC for sequencing
EthA4-F ggcagcgaagcctgactggccgcggaggtg Amplification of ethA for sequencing
EthA6-R tgggcggggtgacattcgttccgggcgatatcg Amplification of ethA for sequencing
mmaA4-F aggcgttccgaatgggctacatcg Amplification of mmaA4 for sequencing
mmaA4-R cgaagttgcgggtgatggatgg Amplification of mmaA4 for sequencing
F and R stand for forward and reverse, respectively.
doi:10.1371/journal.pone.0053162.t001
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127, 3 (Ar), 31.5 (CH3), 21.7 (CH3); umax (cm
–1): 3422.7, 3274.2
(NH); 1525.1 (C=N); 1211.9 (C=S); CHN analysis Found: C,
57.89; H, 6.43; N, 20.45; S, 15.98. Required for C10H13N3S, C,
57.94; H, 6.32; N, 20.27; S, 15.43.
Synthesis of 4-methylbenzylidene-N-phenyl-hydrazinecar-
bothioamide (4). The title compound was obtained as a white
solid (1.2 g, 68.9%) using the general procedure. m.p 192–193uC;
1H NMR (400 MHz, DMSO-d6) d 10.75 (1H,s), 8.48 (1H,s), 7.72
(4H, m), 7.21 (4H, m), 6.82 (1H, m), 2.34 (3H, s), 2.03 (2H, m);
13C NMR (400 MHz, DMSO-d6) d 179.2 (C=S), 147.0 (C=N),
141.5 (Ar), 140.6 (Ar), 129.5 (Ar), 128.4 (Ar), 126.6 (Ar), 125.7
(Ar), 122, 6 (Ar), 21.5 (CH3); umax (cm
–1): 3437.6, 3239.2 (NH);
1578.9 (C=N); 1289.9 (C=S); CHN analysis Found: C, 67.01; H,
5.68; N, 15.82; S, 11.87. Required for C15H15N3S, C, 66.88; H,
5.61; N, 15.60; S, 11.90.
Synthesis of 4-Ethylbenzylidenehydrazinecarbothioamide
(5). The title compound was obtained as a white solid (0.94 g,
44.2%) using the general procedure. m.p 133–134uC; 1H NMR
(400 MHz, DMSO-d6) d 10.01 (1H, s), 7.92 (s, 1H), 7.56 (2H, d,
J = 8.2 Hz), 7.24 (2H, d, J = 8.2 Hz), 6.54 (2H, s), 2.66 (2H, d,
J = 7.6 Hz), 1.26 (3H, t, J = 7.6 Hz); 13C NMR (400 MHz,
DMSO-d6) d 178.37 (C=S), 146.45 (CH=N), 142.90 (Ar),
132.32 (Ar), 128.67 (Ar), 127.94 (Ar), 28.67 (alk), 15.98 (alk); umax
(cm–1): 3402, 3248, 3154.5 (NH); 1594 cm–1 C=N; 1534 cm–1
C=S; CHN analysis: Found: C, 57.56; H, 5.93; N, 20.09; S,
15.33. Required for C10H13N3S1: C, 57.97; H, 6.28; N, 20.29; S,
15.46.
Synthesis of N-methyl-2-(4-ethylbenzylidene)hydrazine-
carbothioamide (6). The title compound was obtained as a
white solid (1.3 g, 74.6%) using the general procedure. m.p 183–
184uC; 1H NMR (400 MHz, DMSO-d6) d 10.12 (1H,s), 8.42
(1H,s), 7.82 (2H, d, J = 8.4 Hz), 7.36 (2H, d, J = 8.4 Hz), 2.92 (3H,
s), 2.63 (2H, q, J = 7.2 Hz), 2.10 (2H, s), 1.32 (3H, t, J = 7.2 Hz);
13C NMR (400 MHz, DMSO-d6) d 178.4 (C=S), 147.0 (C=N),
146.8 (Ar), 139.5 (Ar), 129.3 (Ar), 128.4 (Ar), 31.4 (alk), 28.4 (alk),
14.8 (alk); umax (cm
–1): 3359.4, 3430.7 (NH); 1567.3 (C=N);
1235.7 (C=S); CHN analysis Found: C, 60.02; H, 6.75; N, 18.68;
S 13.97. Required for C11H15N3S, C, 59.69; H, 6.83; N, 18.99; S,
14.49.
Synthesis of 4-ethylbenzylidene-N-phenyl-hydrazine-
carbothioamide (7). The title compound was obtained as a
white solid (1.5 g, 56.7%) using the general procedure. m.p 189–
191uC; 1H NMR (400 MHz, DMSO-d6) d 10.12 (1H,s), 8.42
(1H,s), 7.76 (4H. m), 7.32 (2H, d, J = 8.4 Hz), 7.22 (2H, t,
J = 8.4 Hz), 6.92 (1H, m), 4.23 (1H, s), 2.64 (2H, q, J = 6.8 Hz),
2.13 (1H,s), 1.32 (3H, t, J = 6.8 Hz); 13C NMR (400 MHz,
DMSO-d6) d 178.4 (C=S), 147.0 (C=N), 146.8 (Ar), 139.6 (Ar),
139.5 (Ar), 130.9 (Ar), 129.4 (Ar), 129.6 (Ar), 128.9 (Ar), 127.8
(Ar), 28.9 (alk), 14.7 (alk); umax (cm
–1): 3475.4, 3260.1 (NH);
1525.9 (C=N); 1269.0.2 (C=S); CHN analysis Found: C, 67.92;
H, 6.12; N, 14.74; S 11.03. Required for C16H17N3S, C, 67.81; H,
6.05; N, 14.83; S, 11.31.
Synthesis of 4-propylbenzylidenehydrazinecarbothioamide
(8). The title compound was obtained as a white solid (0.82 g,
37.1%) using the general procedure. m.p 148–149uC; 1H NMR
(400 MHz, DMSO-d6) d 11.40 (1H, s), 8.17 (1H, s), 7.95 (1H, s),
7.70 (2H, d, J = 8.3 Hz), 7.22 (2H, d, J = 8.3 Hz), 2.13 (2H, t,
J = 7.4 Hz), 1.59 (2H, m), 0.89 (3H, t, J = 7.6 Hz); 13C NMR
(400 MHz, DMSO-d6) d 178.44 (C=S), 144.92 (Ar), 142.97
(CH=N), 132.41 (Ar), 129.32 (Ar), 127.93, 31.33 (alk), 24.58 (alk),
14.27 (alk); umax (cm
–1): 3402, 3215, 3156 (NH); 1594 (C=N);
1291 (C=S); CHN analysis: Found: C, 59.68; H, 6.39; N, 19.00;
S, 14.48; Required for C11H15N3S1: C, 59.73; H, 6.79; N, 19.00;
S, 14.48.
Synthesis of 4-isopropylbenzylidenehydrazinecarboth-
ioamide (9). The title compound was obtained as a white solid
(0.68 g, 30.8%) using the general procedure.m.p 151–153uC; 1H
NMR (400 MHz, DMSO-d6) d 9.37 (1H, s, NH2), 7.89 (1H,s),
7.57 (2H, d, J = 8.3 Hz), 7.25 (2H, d, J-8.3 Hz), 6.46 (2H, s), 2.94
(1H, m), 1.25 (6H, s); 13C NMR (400 MHz, DMSO-d6) d 178.4
(C=S), 151.0 (Ar), 142.9 (Ar), 132.0 (Ar), 128.9 (Ar), 127.2 (Ar),
34.3 (CH3)2), 23.84 (CH); umax (cm
–1): 3409, 3276, 3152 (NH);
1599 (C=N); 1281.9 (C=S); CHN analysis Found: Found: C,
59.54; H, 6.22; N, 19.01; S, 14.38 Required for C11H15N3S: C,
59.73; H, 6.79; N, 19.00; S, 14.48.
Synthesis of 2-methoxybenzylidenehydrazinecarboth-
ioamide (10). The title compound was obtained as a white
solid (1.6 g, 85.3%) using the general procedure. m.p 212–213uC;
1H NMR (400 MHz, DMSO-d6) d 8.32 (1H, s), 8.51 (2H, s), 7.65
(1H, d, J = 8.1 Hz), 7.55 (1H, m), 7.23 (1H, d, J = 8.4 Hz), 7.12 (1
H, t, J = 8.1 Hz), 3.88 (3H, s), 2.8 (1H,s); 13C NMR (400 MHz,
DMSO-d6) d 179.1 (C=S), 160.1 (Ar), 145.2 (C=N), 134, 2 (Ar),
132.1 (Ar), 130.5 (Ar), 116.7 (Ar), 110.5 (Ar), 55.3 (OCH3); umax
(cm–1): 3432.0, 3273.9, 3153.2 (NH); 1583 cm–1 (C=N);
1274 cm–1 (C=S); CHN analysis Found: C51.44,; H, 4.53; N,
19.97; S, 15.88.Required for C9H11N3OS: C, 51.65; H, 5.30; N,
20.08; S, 15.38.
Synthesis of 3-methoxybenzylidenehydrazinecarboth-
ioamide (11). The title compound was obtained as a white
solid (1.2 g, 75.0%) using the general procedure. m.p 194–195uC;
1H NMR (400 MHz, DMSO-d6) d 11.45 (1H,s); 8.25 (1H s) 8.08
(1H, s) 8.00 (1H, d, J = 8.4 Hz), 7.44 (1H, d, J-8.4 Hz); 7.27 (1H, t,
J = 8.3 Hz); 6.95 (1H, d, J = 8.3 Hz); 3.79 (3H, s), 2.3 (1H, s); 13C
NMR (400 MHz, DMSO-d6) d 179.3 (C=S), 162.1 (Ar), 146.2
(C=N), 131.2 (Ar), 129.3 (Ar), 128.2(Ar), 112.7 (Ar), 113.2 (Ar),
54.9 (OCH3); umax (cm
–1): 3433.1, 3273.5, 3148.2 (NH);
1587.5 cm–1 (C=N); 1269.2 cm–1 (C=S); CHN analysis Found:
C51.44,; H, 4.97; N, 20.15; S, 15.61.Required for C9H11N3OS:
C, 51.65; H, 5.30; N, 20.08; S, 15.38.
Synthesis of 4-methoxybenzylidenehydrazinecarboth-
ioamide (12). The title compound was obtained as a white
solid (1.7 g, 83.0%) using the general procedure. m.p 167–168uC;
1H NMR (400MHz, DMSO-d6) d 11.30 (1H, s), 8.12 (1H, s), 7.99
(1H, s), 7.92 (1H, s), 7.57 (2H, d, J = 8.2 Hz), 6.96 (2H, d,
J = 8.2 Hz), 3.79 (3H, s); 13C NMR (400 MHz, DMSO-d6) d 179.3
(C=S), 160 (Ar); 142.5 (C=N); 114.7 (Ar); 126 (Ar); 129.47 (Ar),
56.1 (OCH3); umax (cm
–1): 3397, 3248.2,(NH); 1596 (C=N), 1232
(C=S); CHN analysis Found C, 50.63 H, 5.30, N, 20.14 S, 15.25;
Required for C9H11N301S1 (Required for C 51.97; H, 5.26; N,
20.09; S, 15.31.
Synthesis of 4-methoxybenzylidene-N-phenylhydrazine-
carbothioamide (13). The title compound was obtained as a
white solid (1.9 g, 67.7%) using the general procedure. m.p 174–
175uC; 1H NMR (400 MHz, DMSO-d6) d 8.16 (1H, s), 7.76 (2H,
d, J = 8.6 Hz), 7.59 (2H, d, J = 8.3 Hz), 7.13 (2H, t, J = 8.3 Hz),
7.02 (2H, d, J = 8.6 Hz), 6.74 (1H, s), 4.9 (1H, s), 3.76 (3H, s), 1.8
(1H, s); 13C NMR (400 MHz, DMSO-d6) d 180.1 (C=S), 162.9
(Ar), 147.3 (C=N), 139.8 (Ar), 130.4 (Ar), 128.9 (Ar), 128.0 (Ar),
125.6 (Ar), 125.1 (Ar), 113.8 (Ar), 57.3 (OCH3); umax (cm
–1):
3352.2, 3141.5 (NH) (NH), 1606 (C=N); 1242(C=S); CHN
analysis Found: C, 63.15; H, 5.41; N, 14.82; S 11.65, (Required
for C15H1 N3S), C, 63.13; H, 5.30; N, 14.73; S, 1.24).
Synthesis of 4-methoxybenzylidene-N-methylhydrazine-
carbothioamide (14). The title compound was obtained as a
white solid (1.86 g, 80.1%) using the general procedure.m.p 202–
203uC; 1H NMR (400 MHz, DMSO-d6) d 11.38 (1H, s), 8.44 (1H,
s), 7.99 (1H, s), 7.75 (2H, d, J-8.4Hz), 6.99 (2H, d, J = 8.4Hz),
3.01(3H, s), 3.80 (3H, s); 13C NMR (400 MHz, DMSO-d6) d 178.5
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(C= S), 160.4 (Ar), 141.0 (C=N), 129.4 (Ar), 114.2 (Ar), 55.87
(OCH3), 15.28 (CH3-NH); umax (cm
–1): 3317.4, 3154 (NH),; 1599
(C=N); 1251(C=S); CHN analysis Found: C53.87; H, 5.99; N,
18.89; S 14.68,. (Required for C10H13N30S, C, 53.81; H, 5.81, N,
18.83, S, 14.35.
Synthesis of 4-Ethoxybenzylthiosemicarbamide
(15). The title compound was obtained as a white solid (1.4 g,
33.9%) using the general procedure. m.p 155–157uC; 1H NMR
(400 MHz, DMSO-d6) d 11.25 (1H, s), 8.12 (2H, s,), 8.0 (2H, s,);
7.73 (2H, d, J = 8.3 Hz), 6.95 (2H, d, J = 8.3 Hz), 4.05(2H, q,
J = 7.4Hz), 1.33(3H, t, J = 7.4Hz.; 13C NMR (400MHz, DMSO-
d6) d 178.14 (C=S), 160.53 (Ar); 142.80 (C=N), 129.49 (Ar),
127.15 (Ar), 115.11 (Ar); 63.78 (Alk), 15.15 (Alk); umax (cm
–1):
3419.7, 3244.2 (NH); 1170.1 (C=S); 1595 (C=N); CHN analysis
Found: C, 53.82; H, 5.75; N, 18.91; S, 14.59. Required for
C10H13N3OS, C, 53.79; H, 5.87; N, 18.82; S, 14.36).
Synthesis of 4-ethoxybenzylidenehydrazinecarbothioa-
mide (16). The title compound was obtained as a white solid
(1.2 g, 45.2%) using the general procedure. m.p 156–157uC; 1H
NMR (400MHz, DMSO-d6) d 11.40 (2H, s) 8.11 (1H, s), 7.98 (1H,
s), 7.71 (2H, d, J = 8.3 Hz); 6.9 (2H, d, J = 8.3Hz); 4.1 (2H, t,
7.4 Hz); 2.01 (2H, p, J = 7.5 Hz), 1.32 (3H, t, 7.4Hz); 13C NMR
(400 MHz, DMSO-d6) d; 179.2 (C=S), 161.3 (Ar), 147.4 (C=N),
130.3 (Ar), 125.8 (Ar), 118.3 (Ar), 71.2 (alk), 24, 2 (alk), 10.1 (alk);
umax (cm
–1): 3434.0, 32765.9, 3153.2 (NH); 1594 cm21 (C=N);
1287 cm21 (C=S); CHN analysis Found: C, 53.73; H, 5.69; N,
18.70; S, 14.30. Required for C11H15N3OS: C, 53.79; H, 5.87; N,
18.82; S, 14.36).
Synthesis of 4-Butoxybenzylthiosemicarbamide
(17). The title compound was obtained as a white solid (3.1 g,
70.7%) using the general procedure. m.p 170–176uC; 1H NMR
(400MHz, DMSO-d6) d 11.26 (1H, s); 8.12, 7.92 (1H, s); 8.0(2H,s);
7.71 (2H, d, J = 8.4Hz); 6.95 (2H, d, J = 8.4Hz); 3.98(2H, t,
J = 7.6Hz); 1.68 (2 H, q, J = 7.6Hz); 1.43 (2H, sext, J = 7.6Hz);
0.92 (3H, t, J = 7.4Hz); 13C NMR (400MHz, DMSO-d6) d 178.1
(C=S), 142.8 (C=N), 160.71 (Ar), 129, 54 (Ar), 127.15 (Ar),
115.14 (Ar), 67.84 (alk), 31.25 (alk), 19.29 (alk); umax (cm
21):
3425.7, 3221.2 (NH); 1565.4 (C=N); 1241.1 (C=S); CHN
analysis Found: C, 57.29; H, 6.90; N, 16.89; S, 13.01. Required
for C12H17N3OS, C, 57.34; H, 6.82; N, 16.72; S, 12.76).
Synthesis of 4-phenoxybenzylidenehydrazinecarbothioa-
mide (18). The title compound was obtained as a white solid
(1.85 g, 68.3%) using the general procedure. m.p 145–146uC; 1H
NMR (400MHz, DMSO-d6) d 10.01 (1H, s), 8.17 (3H, m); 7.82
(2H, d, J = 8.4Hz); 7.42 (2H, m); 7.08 (5H, m); 13C NMR
(400MHz, DMSO-d6) d and 159.1, 158.2 (Ar), 141 (C=N), 130.8
(Ar), 129.8 (Ar), 179 (C=S), 124.6 (ArC=N), 118.81 (Ar), 119.85
(Ar); umax (cm
21): 3387, 3245, 3143 (NH); 1587 (C=N), 1238
(C=S); CHN analysis Found: Found: C, 65.78; H, 4.75; N, 15.98;
Required for C14H13N3S: C, 65.85; H, 5.13; N, 16.46, S, 12.56.
Synthesis of 2-Flurobenzylidenehydrazinecarbothioa-
mide (19). The title compound was obtained as a white solid
(0.46 g, 24%) using the general procedure.m.p 184–186uC; 1H
NMR (400MHz, DMSO-d6) d 11.58 (1H, s); 8.27 (2H, m),
8.10(1H, s), 7.44 (2H, m, CH), 7.24 (2H, m); 13C NMR (400MHz,
DMSO-d6) d; 178.2 (C=S), 160.3 (Ar), 143.5 (C=N), 133.5 (Ar),
130.2 (Ar), 125.6 (Ar), 120.5 (Ar), 120.1 (Ar), 115.5 (Ar); umax
(cm21): 3433.4, 3254.1 (NH), 1592.5 (C=N), 1175 (C=S); CHN
analysis Found: C, 48.37; H, 3.54; N, 20.99; S, 16.59; (Required
for C9H9N3SF: C, 48.69; H, 4.09; N, 21.31; S, 16.27).
Synthesis of 3-Flurobenzylidenehydrazinecarbothioa-
mide (20). The title compound was obtained as a white solid
(0.5 g, 26%) using the general procedure. m.p 188–189uC; 1H
NMR (400MHz, DMSO-d6) d 11.53 (1H, s), 8.28 (1H, s), 8.18
(1H, s), 8.02 (1H, s), 7.83 (1H, d, J = 8.4Hz), 7.51 (1H, d,
J = 8.4Hz), 7.44 (1H, m), 7.21 (1H, t, J = 8.5 Hz); 13C NMR
(400MHz, DMSO-d6) d; 178.1 (C=S), 154.3 (Ar), 143.1 (C=N),
132.9 (Ar), 131.0 (Ar), 127.7 (Ar), 126.2 (Ar), 122.3 (Ar), 113.5
(Ar); umax (cm
21): 34329.4, 3253.9, (NH), 1590.5 (C=N), 1172.1
(C=S); CHN analysis Found: C, 48.36; H, 3.81; N, 21.22; S,
16.65; (Required for C9H9N3SF: C, 48.69; H, 4.09; N, 21.31; S,
16.27).
Synthesis of 4-flurobenzylidenehydrazinecarbothioamide
(21). The title compound was obtained as a white solid (0.8 g,
43.2%) using the general procedure. m.p 189–191uC; 1H NMR
(400MHz, DMSO-d6) d 11.55 (1H, s) 8.22 (1H, s), 8.04 (2H, s),
7.88 (2H, d, J = 8.4Hz), 7.24 (2H, d, J = 8.4Hz), 13C NMR
(400MHz, DMSO-d6) d; 178.1 (C=S), 154.3 (Ar), 143.1 (C=N),
132.9 (Ar), 131.0 (Ar), 127.7 (Ar), 126.2 (Ar), 122.3 (Ar), 113.5
(Ar); umax (cm
21): 3432.94, 3252.1, (NH), 1592.1 (C=N), 1170.9
(C=S); CHN analysis Found: C, 48.51; H, 3.61; N, 21.08; S,
16.46; (Required for C9H9N3SF: C, 48.69; H, 4.09; N, 21.31; S,
16.27).
Synthesis of 4-fluorobenzylidene-N-methylhydrazine-
carbothioamide (22). The title compound was obtained as a
white solid (0.7 g, 65.7%) using the general procedure.m.p 194–
195uC; 1H NMR (400 MHz, DMSO-d6) d 10.01 (1H,s), 8.43
(1H,s), 7.86 (2H, d, J = 8.4Hz), 7.38 (2H, d, J = 8.4 Hz), 2.81 (3H,
t, J = 7.2Hz); (2.01 (2H, s); 13C NMR (400MHz, DMSO-d6) d
178.4 (C=S), 163.6 (Ar), 147.0 (C=N), 143.4 (Ar), 138.2 (Ar),
128.3 (Ar), 31.4 (CH3); umax (cm
21): 3325.3, 3466.4 (NH); 1527.1
(C=N); 1267.2 (C=S); CHN analysis Found: C, 51.23; H, 4.76;
N, 19.21; S 14.92. Required for C9H10FN3S, C, 51.17; H, 4.77; N,
19.89; S, 15.18.
4-fluorobenzylidene-N-phenylhydrazinecarbothioamide
(23). The title compound was obtained as a white solid (0.7 g,
66.6%) using the general procedure.m.p 198–200uC; 1H NMR
(400MHz, DMSO-d6) d 10.21 (1H,s), 8.43 (1H,s), 7.82 (2H, d,
J = 8.4Hz), 7.74 (2H, d, J = 8.4 Hz), 7.36 (2H, m), 7.21 (2H, m),
6.83 (1H, t, J = 8.5 Hz), (1.97 (2H, s); 13C NMR (400MHz,
DMSO-d6) d 178.4 (C=S), 165.7 (Ar), 147.0 (C=N), 138.5 (Ar),
130.6 (Ar), 129.6 (Ar), 129.2 (Ar), 129.0 (Ar), 126.6 (Ar), 117.6
(Ar); umax (cm
21): 3329.1, 3423.6 (NH); 1565.9 (C=N); 1237.3
(C=S); CHN analysis Found: C, 61.58; H, 4.56; N, 15.65; S
11.89. Required for C14H12F N3S, C, 61.52; H, 4.43; N, 15.37; S,
11.73.
Synthesis of 2-chlorobenzylidenehydrazinecarbothioa-
mide (24). The title compound was obtained as a white solid
(1.2 g, 70.1%) using the general procedure. m.p 210–211uC; 1H
NMR (400MHz, DMSO-d6) d 11.5 (1H, s), 8.47 (1H, s), 8.30 (2H,
s), 8.13 (1H, m), 7.48 (1H, m), 7.46 (1H, m), 7.36 (1H, m);
13C
NMR (400MHz, DMSO-d6) d 178.5 (C=S), 139.4 (C=N), 135.6
(Ar), 134.7 (Ar), 132.5 (Ar), 130.1 (Ar), 127.5 (Ar), 126.9 (Ar),
125.7 (Ar); umax (cm
21): 3414.3, 3153.4 (NH); 3153.44, 3248.85
(NH); 1610.59 (C=N); 1278.34 (C=S); CHN analysis Found: C,
44.79; H, 3.73; N, 19.52; S, 15.59. Required for C8H9N3ClS, C,
44.96; H, 3.75; N, 19.67; S, 14.99).
Synthesis of 3-chlorobenzylidenehydrazinecarbothioa-
mide (25). The title compound was obtained as a white solid
(1.1 g, 44.1%) using the general procedure. m.p 200–202uC; 1H
NMR (400MHz, DMSO-d6) d 11.5 (1H, s), 8.47 (1H, s), 8.30 (2H,
s), 8.13 (1H, m), 7.48 (1H. m), 7.46 (1H, m), 7.36 (1H, m);
13C
NMR (400MHz, DMSO-d6) d 178.5 (C=S), 139.4 (C=N), 135.6
(Ar), 134.7 (Ar), 132.5 (Ar), 130.1 (Ar), 127.5 (Ar), 126.9 (Ar),
125.7 (Ar); umax (cm
21): 3390.3, 3152.9 (NH); 1602.6 (C=N);
1165.3 (C=S); CHN analysis Found: C, 44.88; H, 3.61; N, 19.51;
S, 14.92. Required for C8H9N3ClS, C, 44.96; H, 3.75; N, 19.67;
S, 14.99).
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Synthesis of 4-chlorobenzylidenehydrazinecarbothioa-
mide (26). The title compound was obtained as a white solid
(1.6 g, 74%) using the general procedure.m.p 202–203uC; 1H
NMR (400MHz, DMSO-d6) d 11.58 (1H, s), 8.24 (1H, s), 8.08
(1H, s,), 8.02 (1H,s), 7.84 (2H, d, J = 8.3Hz), 7.45 (2H, d,
J = 8.3Hz); 13C NMR (400MHz, DMSO-d6) d 178.6 (C=S), 141.4
(C=N), 134.7 (Ar), 133.7 (Ar), 129.5 (Ar), 129.2 (Ar); umax (cm
21):
3436.0, 3277.9, 3163.2 (NH); 1598 cm21 (C=N); 1282 cm21
(C=S); CHN analysis Found: C, 44.92; H, 3.86; N, 20.06; S,
15.21. Required for C8H8N3ClS: C, 44.97; H, 3.77; N, 19.66; S,
15.01.
Synthesis of 4-chlorobenzylidene-N-methylhydrazinecar-
bothioamide (27). The title compound was obtained as a white
solid (2.1 g, 90.1%) using the general procedure. m.p 205–206uC;
1H NMR (400MHz, DMSO-d6) d 11.49 (1H, s), 8.58 (1H, d,
J = 8.6), 8.01 (1H, s), 7.83 (2H, d, J = 8.3), 7.47 (2H, J = 8.3), 3.01
(3H, d, J = 7.8); 13C NMR (400MHz, DMSO-d6) d 179.8 (C=S),
134.7 (Ar); 140.8 (CH=N); 129.27 (Ar), 39.65 (CH3); umax (cm
21):
3345.4, 3152NH (NH)s; 1594 (C=N), 1261 (C=S); CHN analysis
Found: C, 47.09; H, 4.35; N, 18.46; S, 13.99; C10H12Cl1N3S1;
Required for C12H11N3S1: C, 47.47; H, 4.40; N, 18.24; S, 14.07.
Synthesis of 4-chlorobenzylidene-N-phenylhydrazinecar-
bothioamide (28). The title compound was obtained as a white
solid (2.5 g, 85.5%) using the general procedure.m.p 192–193uC;
1H NMR (400MHz, DMSO-d6) d 11.89 (1H, s), 10.19 (1H, s,),
8.13 (1H, s), 7.97 (2H, J = 8.4Hz); 7.50 (4H, t, J-8.3 Hz); 7.40 (2H,
t, J = 8.3Hz); 7.21 (1H, d, J = 8.4 Hz); 13C NMR (400MHz,
DMSO-d6) d 176.7 (C=S), 142.0 (C=N), 139.6 (Ar), 126.0 (Ar),
135.3 (Ar); 126.7 (Ar); umax (cm
21): 3308, 3132 (NH); 1592
(C=N), 1260 (C=S); CHN analysis Found: C, 58.03; H, 4.15; N,
14.51; Cl, 12.26; S, 11.05; C10H12Cl1N3S1; Required for
C12H11N3S1: C, 57.51; H, 4.14; N, 14.44; Cl, 12.01; S, 10.56.
Synthesis of 2-bromobenzylidenehydrazinecarbothioa-
mide (29). The title compound was obtained as a white solid
(0.53 g, 67.8%) using the general procedure. m.p 202–203uC; 1H
NMR (400MHz, DMSO-d6) d 11.7 (1H, s) 8.43 (2H, s); 8.29 (1H,
t, J = 8.5Hz); 8.28 (2H, t, J = 8.4Hz); 8.12 (1H, s); 7.64 (1H, d, J-
8.5Hz); 13C NMR (400MHz, DMSO-d6) d 178.4 (C=S), 143.8
(C=N), 136.7 (Ar), 136.1 (Ar), 133.1 (Ar), 130.2 (Ar), 128.6 (Ar),
120.1 (Ar); umax (cm
21): 3435.9; 3285.1 (NH); 1599.6 (C=N);
1170.3 (C=S); CHN analysis Found: C, 37.17; H, 2.84; N, 16.13;
S, 12.66. Required for BrC8H8N3: S: C, 37.1; H, 3.09; N, 16.2; S,
12.4.
Synthesis of 3-bromobenzylidenehydrazinecarbothioa-
mide (30). The title compound was obtained as a white solid
(1.1 g, 72.3%) using the general procedure. m.p 212–213uC; 1H
NMR (400MHz, DMSO-d6) d 11.51 (1H, s); 8.29 (2H, s); 8.2 (1H,
d, J = 8.4 Hz); 8.0 (1H, s); 7.69 (1H, d, J = 8.3Hz); 7.56 (1H, d,
J = 8.3Hz); 7.35 (1H, t, J = 8.4Hz); 13C NMR (400MHz, DMSO-
d6) d 178.2 (C=S), 143.5 (C=N), 135.7 (Ar), 134.2 (Ar), 134.0
(Ar), 132.2 (Ar), 129.6 (Ar), 122.1 (Ar); umax (cm
21): 3434.2;
3282.4 (NH); 1598.9 (C=N); 1168.9 (C=S); CHN analysis
Found: C, 37.18; H, 2.81; N, 16.13; S, 12.88. Required for
BrC8H8N3: S: C, 37.1; H, 3.09; N, 16.2; S, 12.4.
Synthesis of 4-bromobenzylidenehydrazinecarbothioa-
mide (31). The title compound was obtained as a white solid
(1.2 g, 69.5%) using the general procedure. m.p 225–226uC; 1H
NMR (400MHz, DMSO-d6) d 11.66 (1H, s) 8.43 (2H, s); 8.33 (2H,
d, J = 8.4Hz); 8.28 (2H, d, J = 8.4Hz); 8.13 (1H, s); 13C NMR
(400MHz, DMSO-d6) d 178.0 (C=S), 143.0 (C=N), 135.7 (Ar),
133.6 (Ar), 133.3 (Ar), 130.5 (Ar), 129.9 (Ar), 120.4 (Ar); umax
(cm21): 3435.1; 3280.2 (NH); 1593.5 (C=N); 1170.4 (C=S);
CHN analysis Found: C, 37.24; H, 2.85; N, 16.00; S, 13, 23.
Required for BrC8H8N3: S: C, 37.1; H, 3.09; N, 16.2; S, 12.4.
Results and Discussion
Isolation of M. tuberculosis Spontaneous Mutants
Resistant to TAC and SRI-224
A TAC analogue, SRI-224, was previously tested against
Mycobacterium avium and found to be more effective than TAC
in vitro and in mice [30], and has also been shown to be very active
against M. tuberculosis [20]. To continue our studies on the
antitubercular activity of TAC, we selected TAC-resistant M.
tuberculosis mutants by plating actively-growing cultures on
Middlebrook 7H10 media supplemented with OADC and either
TAC or SRI-224 at concentrations that were 10 to 40 times higher
than the minimum inhibitory concentration (MIC99). The ten
mutants that were obtained, labeled MTTR2 through MTTR28,
are listed in Table 2, which indicates the concentration of the drug
on which these were selected and shows that most mutants
exhibited comparably high levels of resistance to both TAC and
SRI-224, with MIC values $20 mg/ml compared to the MIC of
0.25 mg/ml for the parental strain, as previously reported [23].
Mycolic Acid Profile in the M. tuberculosis TAC Resistant
Mutants
Several recent studies highlighted the possible link between
TAC activity and the mycolic acid biosynthetic pathway. First, we
originally demonstrated that TAC inhibits mycolic acid biosyn-
thesis [17], although the profile was different from that generated
with ETH treatment, a drug that is known to target the enoyl-ACP
reductase of FAS-II. Second, we demonstrated that inhibition of
cyclopropanation of mycolic acids is one of the effects of treatment
with TAC or its analogue SRI-224, thus providing strong evidence
linking the mode of action of TAC with mycolic acid metabolism
[20]. Third, subsequent work identified an important set of TAC-
resistant BCG and M. tuberculosis mutants that were lacking keto-
mycolic acids due to mutations within the mmaA4 gene [23].
Further, overexpression of mmaA4 in BCG resulted in increased
susceptibility to TAC. MmaA4 (also known as Hma) is an S-
adenosylmethionine (SAM)-dependent methyltransferase required
to produce the hydroxymycolate precursor of the oxygenated
mycolic acid [15]. A recent study identified mutations in the b-
hydroxyacyl ACP dehydratase complex of the FAS-II system
capable of conferring resistance to TAC in M. tuberculosis and M.
kansasii [24]. In addition, it was shown that exposure of M.
tuberculosis to TAC was associated to an accumulation of 3-hydroxy
fatty acids, the dehydratase substrates [25], thus providing an
additional proof that activity of TAC is highly interconnected with
mycolic acid biosynthesis [24]. This growing body of evidence
connecting TAC activity and TAC-resistance mutations to
mycolic acid metabolism prompted us to examine the mycolic
acid profile of all 10 mutant strains (Fig. 1).
Fatty acid methyl esters (FAMEs) and mycolic acid methyl esters
(MAMEs) were extracted from exponentially growing cultures,
resolved by thin layer chromatography (TLC) and visualized
following charring with molybdophosphoric acid. As shown in
Fig. 1, all mutants exhibited a standard profile compared to the
parental strain with the notable exception of MTTR13, which
produces almost exclusively a-mycolic acids with very limited
amounts of methoxy- and keto-mycolic acids. Because MmaA4 is
required for the synthesis of oxygenated mycolic acids [15] and
TAC-resistant strains lacking oxygenated mycolic acids have been
identified previously, it seemed likely that MTTR13 had a
mutation in mmaA4. However, as this was the only one of the
ten TAC-resistant strains with this mycolic acid pattern, it was
clear that other mechanisms of TAC resistance must be operating.
Efficient TAC Analogues against M. tuberculosis
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e53162
Genotype of the TAC-associated Resistance Markers
To characterize these additional mutations conferring TAC
resistance in our strains, we sequenced the genes encoding all
proteins known to be associated with TAC resistance, namely ethA,
mmaA4 and hadABC. As shown in Table 2, no mutations were
found in ethA, indicating that resistance was not mediated by a
defect in the TAC activation process. As expected, a mutation in
mmaA4 was found only in mutant MTTR13, consistent with the
lack of oxygenated mycolates in this strain (Fig. 1). Interestingly,
the Gly101Asp mutation in MmaA4 had not been identified in
BCG mutants resistant to TAC [23], but was found in an M.
tuberculosis strain resistant to TAC [24].
Among the remaining nine strains that were not mutated in
mmaA4, six (MTTR3, MTTR5, MTTR6, MTTR11, MTTR19,
MTTR28) had mutations in hadA, and the remaining three
(MTTR2, MTTR14, and MTTR18) harbored mutations in hadC.
All of the hadA mutants were missense mutations at Cys61,
replacing it either with a Gly or a Ser. The Cys61Ser substitution
was described previously in a TAC-resistant mutant of M.
tuberculosis and also a TAC-resistant M. kansasii strain [24]. In
contrast, the missense mutations in hadC were more varied, with
substitutions occurring in Val85, Lys157 and Thr123. Only the
mutations in Val85 and Ala151 were reported previously in M.
kansasii and M. tuberculosis, respectively, so our study extends the
sites of mutations in HadC associated with TAC resistance.
Mapping these mutations on the three-dimensional structures of
HadA or HadC would greatly help to understand the impact of
these mutations on dehydratase activity or the interactions of these
proteins with other FAS-II components, but adequate structures of
these proteins are not yet available. MTTR3, MTTR13 and
MTTR18 grew similarly to the wild-type strain in broth medium,
indicating that mutations in hadA, hadC or mmaA4 do not confer a
growth defect (data not shown). As in the study by Belardinelli and
Morbidoni [24], we failed to identify missense mutations in hadB.
Taken together, these results support the conclusion that resistance
to TAC inM. tuberculosis can be attributed to missense mutations in
either mmaA4, hadA or hadC and, at least in our mutant strains, the
C61G mutation in HadA is the most common amino acid change
associated with TAC resistance.
Table 2. Susceptibility and genetic mutations associated to TAC resistance in M. tuberculosis strains selected on high
concentrations of TAC or SRI-224.
M. tuberculosis
strains
Drug
selection
(mg/ml)
MIC TAC
(mg/ml)
MIC SRI-224
(mg/ml)
Keto
mycolates
mmaA4
mutation
(AA change)
ethA mutation
(AA change)
hadA mutation
(AA change)
hadB
mutation
(AA change)
hadC
mutation
(AA change)
MTTR2 TAC 2,5 .20 20 + none none none none a367g (T123A)
MTTR3 TAC 2,5 .20 20 + none none t181g (C61G) none none
MTTR5 TAC 2,5 .20 20 + none none t181g (C61G) none none
MTTR6 TAC 2,5 20 20 + none none t181a (C61S) none none
MTTR11 TAC 5 .20 20 + none none t181g (C61G) none none
MTTR13 TAC 5 20 5 - g302a (G101D) none none none none
MTTR14 TAC 5 .20 20 + none none none none a470g (K157R)
MTTR18 SRI-224 2,5 20 10 + none none none none g253t (V85F)
MTTR19 SRI-224 2,5 10–20 20 + none none t181g (C61G) none none
MTTR28 SRI-224 10 .20 20 + none none t181g (C61G) none none
Parental 0,25 0,1 + none none none none none
doi:10.1371/journal.pone.0053162.t002
Figure 1. Mycolic acid profile of the parental M. tuberculosis strain and independent TAC-resistant derived mutants. FAMEs and
MAMEs were extracted from exponentially growing cultures and resolved by single dimension TLC in hexane/ethyl acetate (19/1, v/v) prior to
visualization using molybdophosphoric acid and charring. a, a-mycolic acids; methoxy, methoxy-mycolic acids; keto, keto-mycolic acids.
doi:10.1371/journal.pone.0053162.g001
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Because drug resistance can be generated by increased levels of
the specific target, we explored whether resistance to TAC in the
MTTR mutants is associated with the overexpression of HadA
and/or HadC. Quantitative real-time PCR was performed to
determine the expression levels of the hadA (Fig. 2A) and hadC
(Fig. 2B) transcripts in representative members of the different
mutant classes: MTTR3 (containing the C61G substitution in
HadA), MTTR13 (containing the G101D substitution in MmaA4)
and MTTR18 (containing the V85F substitution in HadC). The
results clearly demonstrate that in all three mutants the expression
of hadAB and hadBC is comparable to that of the parental strain
(Fig. 2), showing that point mutations in HadA or HadC do not
alter their levels expression. In addition, these results exclude the
presence of additional mutations within the hadABC operon driving
overexpression of the target genes, as has been described for the
C15T inhA promoter mutation that confers INH resistance by
increasing the transcription of inhA [5].
Synthesis and Activity of TAC-related Analogues against
M. tuberculosis
Due to the low cost of TAC, it was widely used in combination
with INH as a first-line antitubercular therapy in poor countries
[24] and has also been used throughout the developing world [24]
to treat patients infected with multi-drug resistant M. tuberculosis
strains [24,31,32]. However, secondary toxic effects, especially
severe skin reactions in patients co-infected with HIV, led to its
removal from the antitubercular chemotherapeutic portfolio
[33,34]. We reasoned that if new TAC-related compounds could
be identified that have decreased MICs and less severe side-effects,
they could be administered at lower doses and consequently
induce fewer or no side-effects, and thus represent a valuable
alternative for the treatment of drug-resistant strains. Preclinical
pharmacokinetics have identified one such TAC analogue
(KBF611) that is considered suitable for further clinical evaluation
[35]. TAC was therefore chosen as a target pharmacophore for the
preparation of analogues. Having observed that the simple
modification of the parent TAC scaffold to create SRI-224 led
to a greater than two-fold increase in potency, we investigated the
effect of further simple structural modifications. To achieve this
task we prepared a modest library of 31 compounds using a
standard protocol for the generation of imines via the reaction of
thiosemicarbazide, a derivative thereof, and a range of mono-
substituted aromatic aldehydes. All these new TAC-related
compounds were evaluated for their ability to inhibit growth of
M. tuberculosis mc27000 by determining their respective MICs. As
shown in Figure 3, the compounds exhibited a large range of
activity, from very active compounds to analogues exhibiting only
modest or poor activity. In particular, compounds 8, 15, 16, 17
and 18 were found to be 5- to 10-fold more active than the
parental TAC molecule. This extends our previous studies and
confirms that newer, more effective analogues might be developed
for clinical use [20]. The studies described below involve two of
the most effective agents synthesized, 15 and 16, but larger
numbers of analogues will be required to develop a robust
structure-activity relationship for the thiosemicarbazone class of
antitubercular agents.
Structure-activity and Further Considerations for the
Development of the TAC Scaffold
Modification of the aromatic 4-position to give structural
analogues directly related to TAC revealed that O-ethyl 15 and
O-propyl 16 groups were able to increase the potency by 10 fold,
with MIC values of 0.025 mg/ml (Fig. 3). The corresponding ethyl
5 and propyl 8 groups appeared to have result in a smaller
increase in potency, with MIC values of 0.075 mg/ml and 0.5 mg/
ml, respectively, and shorter 2, 3 or bulkier 9 substituents resulted
in even lower potency. Substitution with halogens appeared not to
increase potency although the size of the halogen seemed to
significantly affect the activity of the compounds. When modified
with an F 21 at the 4-position, the MIC was 0.5 mg/ml, but the
MIC decreased when replaced by Cl 26 and increased dramat-
ically with Br 31, yielding MIC values of 0.1 mg/ml and 10 mg/
ml, respectively. Substitution of the aromatic ring at the 2- and 3-
positions resulted in lower potency than the corresponding 4-
position analogues, with the only exception the 4-Br analogue 31,
which was only half as active as analogues 29 and 30.
Interestingly, modification of the carbothiamide section of the
molecule at R5 with either methyl or phenyl dramatically lowered
activity in all cases.
In conclusion, the structure-activity relationships for our set of
compounds indicated that: 1) modification at the 4-position gave
the best activity when a balance of size and flexibility was achieved
with O-propyl and O-ethyl substituents; 2) monosubstitution of the
ring at other positions was not favourable; and 3) modification of
the carbothiamide section was not tolerated.
TAC Analogues 15 and 16 Inhibit M. tuberculosis Mycolic
Acid Biosynthesis
M. tuberculosis carries three types of mycolic acids: di-cyclopro-
panated a-mycolic acids and oxygenated, methoxy- and keto-
mycolic acids. Synthesis of cell wall lipids, particularly mycolic
acids, is essential for survival of mycobacteria in vivo. To evaluate
the effect of TAC analogues on mycolic acid biosynthesis, we
extracted methyl mycolic acids and fatty acid methyl esters from
cultures grown with increasing concentrations of TAC, 15 or 16,
followed by metabolic labeling with [14C]acetate and TLC/
autoradiography analysis. In agreement with previous reports
[17,20,23,24], TAC alters the synthesis of mycolates, especially of
a-mycolic acids (Fig. 4A), while the synthesis of methoxy-mycolic
acids and keto-mycolic acids appeared more resistant to TAC
inhibition, at least at the concentrations tested [24]. This general
effect of TAC on mycolic acid biosynthesis is particularly relevant
to our recent observation that exposure of mycobacteria to TAC is
associated with a decreased production of a cell wall arabinogly-
cerolipid, designated DMAG, for dimycolyl diarabinoglycerol
[36]. Furthermore, inhibition of DMAG production by TAC was
dependent on the presence of a functional MmaA4 [36]. From
these data, it can be inferred that the disappearance of DMAG
following treatment with TAC is a direct consequence of the
inhibition of mycolic acid synthesis.
Analogues 15 and 16 were also found to inhibit a- and
methoxy-mycolic acid synthesis in a dose-dependent manner with
almost complete abrogation of a-mycolic acid biosynthesis at
10 mg/ml (Fig. 4A). Furthermore, a more thorough comparative
analysis of the mycolic acid profile resolved by two-dimensional
silver nitrate-impregnated TLC plates (Fig. 4B) showed that the
inhibition of mycolic acid synthesis was accompanied by a modest,
but reproducible, accumulation of unsaturated mycolic acids,
presumably due to the inhibition of SAM-dependent methyltrans-
ferases involved in introducing cyclopropane rings on the
meromycolates, as reported previously in other mycobacterial
strains [20]. While this effect was very limited following TAC
treatment, accumulation of unsaturated keto-mycolic acid precur-
sors was more pronounced after exposure to higher concentrations
of 15 and 16 (data not shown), consistent with our previous
observations using the SRI-224 analogue [20].
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One would expect that all mycolic acid subspecies would be
inhibited concomitantly, leading to complete cessation in mycolic
acid biosynthesis, as is seen with specific FAS-II inhibitors such as
INH or ETH. FAS-II components are all essential and known to
participate in the meromycolyl-ACP elongation steps, and it is
during this process that the specific methyltransferases involved in
the formation of the meromycolic acid are likely to operate. That
keto-mycolic acids are refractory to TAC inhibition is somehow
intriguing and argues against the HadABC being directly targeted
by TAC. Supporting this view, both the recent study by
Belardinelli and Morbidoni [24] and the present study failed to
identify mutations within the HadB subunit bearing the catalytic
activity. Mutations only occurred in the HadA and HadC
subunits, perhaps stabilizing the complex and presenting the
growing acyl-ACP substrate to HadB [37], thought to be the
enzymatically active component of the complex. Elegant work
demonstrated that the FAS-II system of M. tuberculosis is organized
in specialized interconnected complexes composed of the con-
densing enzymes, dehydratase heterodimers and the methyltrans-
ferases [38,39,40]. This led the authors to propose that because the
interactions amongst these enzymes are crucial and their
disruption detrimental for M. tuberculosis survival, the protein
interactions could represent attractive drug targets. Whether this is
the case for TAC remains to be established experimentally but
seems highly conceivable. Our results also emphasize the
possibility that EthA-activated TAC and related analogues are
likely to inhibit mycolic acid biosynthesis by physically altering the
interactions of HadAB and HadBC dehydratases with other FAS-
II components, particularly those involved in the formation of the
meromycolic acid. The disruption of the interactions between Had
complexes and SAM-dependent methyl transferases (CMAS)
would explain the mycolic acid profile of 15- and 16-treated
mycobacteria: less mycolates (as a result of Had alteration) and
accumulation of the unsaturated precursors (as a result of CMAS
inhibition). Why 15 and 16 are more active than TAC remains
unknown, but they could be more stable and/or more efficient
perturbagenic molecules than TAC. The ability of 15 to inhibit
keto-mycolic acid biosynthesis could be explained by a greater
capacity to disrupt specific interactions between Had complexes
and the still unknown putative redox enzyme that converts the
hydroxymycolate products of MmaA4 into keto-mycolic acids.
While these models are attractive, confirmation will require
further study and more information on the structure of the
Figure 2. HadAB and hadBC expression levels in TAC-resistant M. tuberculosismutants. The parental M. tuberculosis strain as well as MTTR3,
MTTR13 or MTTR18 were grown to mid-log phase. Total RNA was isolated from three independent replicates and the levels of hadAB (A) and hadBC
(B) transcripts relative to those of the sigA gene were measured by quantitative reverse transcription-PCR. Recombinant strains carrying the pVV16-
hadAB or pVV16-hadBC constructs were included as positive controls of HadAB and HadBC overexpression, respectively.
doi:10.1371/journal.pone.0053162.g002
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Figure 3. Structures of chemical analogues of thiacetazone and their corresponding minimum inhibitory concentrations in M.
tuberculosis. Shaded lanes highlight the more efficient analogues.
doi:10.1371/journal.pone.0053162.g003
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proteins, their mode of interaction and how the drugs alter these
interactions.
Overexpression of the Had Heterocomplexes Lead to
High Resistance Levels to TAC Analogues
The above results prompted us to investigate whether overex-
pression of the FAS-II dehydratase would result in resistance to the
TAC analogues. The different HadAB, HadBC or HadABC
heterocomplexes were overproduced in M. tuberculosis by ligating
the corresponding genes into the pMK1 or pVV16 vectors, in
which the genes of interest are under the control of the constitutive
hsp60 promoter and carry either an N-terminal (pMK1) or a C-
terminal (pVV16) His-tag [28]. As previously observed [24],
overexpression of hadAB, hadBC or hadABC led to high-level
resistance to TAC (Table 3). The MICs for hadAB were 10-fold
greater than those of the bacteria carrying the plasmid vector,
Figure 4. Dose-response effects of TAC and related analogues on mycolic acid biosynthesis in M. tuberculosis. The inhibitory effect on
the incorporation of [2-14C]acetate was assayed by labeling in the presence of increasing concentrations of TAC, 15 or 16. The corresponding fatty
acid methyl esters (FAME) and mycolic acid methyl esters (MAME) were extracted and equal counts were loaded onto a TLC plate. (A) 1D TLC
profile of MAMEs. Radiolabeled lipids (40,000 cpm) were resolved with hexane/ethyl acetate (19/1, v/v, 2 runs) and exposed overnight to a film. (B)
2D TLC profile of MAMEs. Radiolabeled lipids (30, 000 cpm) were resolved with hexane/ethyl acetate (19/1, v/v, 2 runs) in the first dimension and
petroleum ether/diethyl ether (17/3, v/v, 3 runs) in the second direction on 10% silver nitrate-impregnated plates and exposed for two days to a film.
A, a-mycolates; keto, ketomycolates, methoxy, methoxymycolates. Arrowheads indicate positions of the unsaturated mycolic acid species. OAME,
oleic acid methyl ester.
doi:10.1371/journal.pone.0053162.g004
Table 3. MIC of TAC and its related analogues 15, 16 and 17
against recombinant M. tuberculosis strains overexpresssing
the different dehydratase complexesa.
compound strain TAC 15 16 17
pMK1 0.25 0.025 0.05 0.05
pMK1_hadAB 2.5 0.25 2.5 0.25
pVV16 0.25 0.025 0.025 0.05
pVV16_hadBC .50 1 .10 1
pMV261_hadABC .50 1 .10 1
aMIC99 expressed in mg/ml was determined by dilution on solid agar medium
7H10 supplemented with OADC.
doi:10.1371/journal.pone.0053162.t003
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while the MICs for bacteria containing the hadBC and hadABC
plasmids were more than 200-fold greater. Similarly, overproduc-
tion of the different heterocomplexes induced high resistance levels
to 15 and 16, with MICs that were 10-fold (15 against a strain
with the hadAB) to 200-fold greater than the MICs of strains with
the vector alone (Table 3). These data suggest that the HadAB and
HadBC heterocomplexes differ in their ability to generate
resistance to the 15 and 16 analogues, which may reflect
differences in their interactions with the target proteins. The
nature of the modification at 4-position of the aromatic ring (O-
ethyl in 15 versus O-propyl in 16) appears critical in defining the
resistance level of the various Had-overproducing strains. This
observation is also supported by the fact that compound 17, that
possesses an additional methyl group compared to 16 (O-butyl at
4-position) exhibits activity levels comparable to 15 against the
Had-overproducing strains (Table 3).
In conclusion, TAC is generally dismissed as a very toxic drug,
but this work suggests that more active analogues with reduced
MIC levels might be effectively administered at significantly lower
doses. While investigating the possible toxic effects of the new
analogues is beyond the scope of this study, the results show that it
is possible to synthesize several more potent analogues, raising the
hope that one can be found for which a lower effective dose will
induce a much lower, acceptable level of side effects. It is clear
from this study that simple modification of the TAC scaffold with
compounds 15 and 16 permits optimisation whilst maintaining the
same sites of action, as these compounds also inhibit mycolic acid
biosynthesis. While further work is required on the structural
modification of this scaffold, our data suggests the possibility of
developing a molecule derived from the TAC structure that
inhibits mycolic acid biosynthesis with a pharmacokinetic/
pharmacodynamic profile that permits lower patient dosing than
with TAC and thus potentially reduces or eliminates the toxicity
associated with the drug. Before these or other TAC analogues can
be seriously considered as potential drugs for the treatment of
MDR or XDR TB, pharmacological and toxicological studies are
needed to test their toxicity. Additionally, solving the structures of
HadA, HadB and HadC would facilitate a better understanding of
the mechanism of action of TAC and its analogues and help to
precisely define how the mutations described here confer
resistance.
Acknowledgments
The authors wish to thank W.R. Jacobs for the generous gift of M.
tuberculosis mc27000, H. Takiff for critically reading the manuscript and
helpful discussions and the University Monptellier 2 for access to the
Genomic qPCR facility.
Author Contributions
Conceived and designed the experiments: GDC LGZ LK. Performed the
experiments: GDC DC RMC EV LGZ LK. Analyzed the data: GDC
LGZ LK. Contributed reagents/materials/analysis tools: GDC DC EV
LGZ LK. Wrote the paper: GDC LGZ LK.
References
1. Mondal R, Jain A (2007) Extensively drug-resistant Mycobacterium tuberculosis,
India. Emerg Infect Dis 13: 1429–1431.
2. Espinal MA (2003) The global situation of MDR-TB. Tuberculosis (Edinb) 83:
44–51.
3. Caminero JA, Sotgiu G, Zumla A, Migliori GB (2010) Best drug treatment for
multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis
10: 621–629.
4. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, et al. (2011)
Depletion of antibiotic targets has widely varying effects on growth. Proc Natl
Acad Sci U S A 108: 4176–4181.
5. Vilcheze C, Wang F, Arai M, Hazbon MH, Colangeli R, et al. (2006) Transfer
of a point mutation in Mycobacterium tuberculosis inhA resolves the target of
isoniazid. Nat Med 12: 1027–1029.
6. Kremer LS, Besra GS (2002) Current status and future development of
antitubercular chemotherapy. Expert Opin Investig Drugs 11: 1033–1049.
7. Bugg TD, Braddick D, Dowson CG, Roper DI (2011) Bacterial cell wall
assembly: still an attractive antibacterial target. Trends Biotechnol 29: 167–173.
8. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, et al. (1994)
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium
tuberculosis. Science 263: 227–230.
9. Wang F, Langley R, Gulten G, Dover LG, Besra GS, et al. (2007) Mechanism of
thioamide drug action against tuberculosis and leprosy. J Exp Med 204: 73–78.
10. Kremer L, Baulard AR, Besra GS (2000) Genetics of mycolic acid biosynthesis.
In Molecular Genetics of Mycobacteria (ed Hatfull, GF, Jacobs, Jr, WR) 173–
190, ASM Press.
11. Takayama K, Wang C, Besra GS (2005) Pathway to synthesis and processing of
mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev 18: 81–101.
12. Ojha AK, Trivelli X, Guerardel Y, Kremer L, Hatfull GF (2010) Enzymatic
hydrolysis of trehalose dimycolate releases free mycolic acids during mycobac-
terial growth in biofilms. J Biol Chem 285: 17380–17389.
13. Glickman MS, Cox JS, Jacobs WR Jr (2000) A novel mycolic acid cyclopropane
synthetase is required for cording, persistence, and virulence of Mycobacterium
tuberculosis. Mol Cell 5: 717–727.
14. Bhatt A, Fujiwara N, Bhatt K, Gurcha SS, Kremer L, et al. (2007) Deletion of
kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent
tuberculosis in immunocompetent mice. Proc Natl Acad Sci U S A 104: 5157–
5162.
15. Dubnau E, Chan J, Raynaud C, Mohan VP, Laneelle MA, et al. (2000)
Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis
in mice. Mol Microbiol 36: 630–637.
16. Kremer L, Dover LG, Carrere S, Nampoothiri KM, Lesjean S, et al. (2002)
Mycolic acid biosynthesis and enzymic characterization of the beta-ketoacyl-
ACP synthase A-condensing enzyme from Mycobacterium tuberculosis. Biochem J
364: 423–430.
17. Dover LG, Alahari A, Gratraud P, Gomes JM, Bhowruth V, et al. (2007) EthA,
a common activator of thiocarbamide-containing drugs acting on different
mycobacterial targets. Antimicrob Agents Chemother 51: 1055–1063.
18. Baulard AR, Betts JC, Engohang-Ndong J, Quan S, McAdam RA, et al. (2000)
Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol
Chem 275: 28326–28331.
19. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE 3rd (2000)
Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium
tuberculosis. Proc Natl Acad Sci U S A 97: 9677–9682.
20. Alahari A, Trivelli X, Guerardel Y, Dover LG, Besra GS, et al. (2007)
Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall
mycolic acids in mycobacteria. PLoS ONE 2: e1343.
21. Rao V, Fujiwara N, Porcelli SA, Glickman MS (2005) Mycobacterium tuberculosis
controls host innate immune activation through cyclopropane modification of a
glycolipid effector molecule. J Exp Med 201: 535–543.
22. Corrales RM, Molle V, Leiba J, Mourey L, de Chastellier C, et al. (2012)
Phosphorylation of mycobacterial PcaA inhibits mycolic acid cyclopropanation:
consequences for intracellular survival and for phagosome maturation block.
J Biol Chem 287: 26187–26199.
23. Alahari A, Alibaud L, Trivelli X, Gupta R, Lamichhane G, et al. (2009) Mycolic
acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in
Mycobacterium tuberculosis. Mol Microbiol 71: 1263–1277.
24. Belardinelli JM, Morbidoni HR (2012) Mutations in the essential FAS II beta-
hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in
Mycobacterium tuberculosis and Mycobacterium kansasii. Mol Microbiol 86: 568–579.
25. Grzegorzewicz AE, Kordulakova J, Jones V, Born SE, Belardinelli JM, et al.
(2012) A common mechanism of inhibition of the Mycobacterium tuberculosis
mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J Biol Chem 287:
38434–38441.
26. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, et al. (2006)
Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating
mutant strain that protects immunocompetent and immunocompromised mice
against experimental tuberculosis. Vaccine 24: 6309–6320.
27. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New
use of BCG for recombinant vaccines. Nature 351: 456–460.
28. Slama N, Leiba J, Eynard N, Daffe M, Kremer L, et al. (2011) Negative
regulation by Ser/Thr phosphorylation of HadAB and HadBC dehydratases
from Mycobacterium tuberculosis type II fatty acid synthase system. Biochem
Biophys Res Commun 412: 401–406.
29. Lutfalla G, Uze G (2006) Performing quantitative reverse-transcribed polymer-
ase chain reaction experiments. Methods Enzymol 410: 386–400.
30. Bermudez LE, Reynolds R, Kolonoski P, Aralar P, Inderlied CB, et al. (2003)
Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobac-
terium avium in mice. Antimicrob Agents Chemother 47: 2685–2687.
Efficient TAC Analogues against M. tuberculosis
PLOS ONE | www.plosone.org 12 January 2013 | Volume 8 | Issue 1 | e53162
31. Davidson PT, Le HQ (1992) Drug treatment of tuberculosis-1992. Drugs 43:
651–673.
32. Nunn P, Porter J, Winstanley P (1993) Thiacetazone-avoid like poison or use
with care? Trans R Soc Trop Med Hyg 87: 578–582.
33. Fegan D (1994) Thiacetazone–use with care. Trans R Soc Trop Med Hyg 88:
714.
34. Fegan D (1995) Use of thiacetazone. Lancet 345: 63.
35. Shahab FM, Kobarfard F, Shafaghi B, Dadashzadeh S (2009) Preclinical
pharmacokinetics of KBF611, a new antituberculosis agent in mice and rabbits,
and comparison with thiacetazone. Xenobiotica 40: 225–234.
36. Rombouts Y, Brust B, Ojha AK, Maes E, Coddeville B, et al. (2012) Exposure of
mycobacteria to cell wall-inhibitory drugs decreases production of arabinogly-
cerolipid related to mycolyl-arabinogalactan-peptidoglycan metabolism. J Biol
Chem 287: 11060–11069.
37. Sacco E, Covarrubias AS, O’Hare HM, Carroll P, Eynard N, et al. (2007) The
missing piece of the type II fatty acid synthase system from Mycobacterium
tuberculosis. Proc Natl Acad Sci U S A 104: 14628–14633.
38. Veyron-Churlet R, Guerrini O, Mourey L, Daffe M, Zerbib D (2004) Protein-
protein interactions within the Fatty Acid Synthase-II system of Mycobacterium
tuberculosis are essential for mycobacterial viability. Mol Microbiol 54: 1161–
1172.
39. Veyron-Churlet R, Bigot S, Guerrini O, Verdoux S, Malaga W, et al. (2005)
The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple
specialized elongation complexes interconnected by specific protein-protein
interactions. J Mol Biol 353: 847–858.
40. Cantaloube S, Veyron-Churlet R, Haddache N, Daffe M, Zerbib D (2011) The
Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the
specificity of the mycolic acid elongation complexes. PLoS One 6: e29564.
Efficient TAC Analogues against M. tuberculosis
PLOS ONE | www.plosone.org 13 January 2013 | Volume 8 | Issue 1 | e53162
